Payment overview · 2025
General Payments
$371.47
26 reported records · 8 companies
Healthcare provider profile · identity verified
Daniel D Carroll, MD
Allopathic & Osteopathic Physicians|Family Medicine · KINGSPORT, TN · NPI 1467428987
Verified facts
What the public records show
CMS Open Payments records show Daniel D Carroll, MD received $371.47 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 40.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $149.93 | 40.4% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.61 | 18.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $63.46 | 17.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.11 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.61 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.02 | 4.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.55 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.18 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $371.47 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $145.57 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $107.74 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.61 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.46 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $4.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 284 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
201 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
284 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1138 | 288 |
| Losartan Potassium | Losartan Potassium | 692 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 679 | 185 |
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 187 |
| Gabapentin | Gabapentin | 629 | 101 |
| Omeprazole | Omeprazole | 576 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 553 | 175 |
| Hydrochlorothiazide | Hydrochlorothiazide | 452 | 127 |
| Lisinopril | Lisinopril | 441 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 126 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 418 | 88 |
| Alprazolam | Alprazolam | 372 | 70 |
| Furosemide | Furosemide | 369 | 101 |
| Famotidine | Famotidine | 367 | 104 |
| Tramadol Hcl | Tramadol Hcl | 365 | 80 |
| Metformin Hcl Er | Metformin Hcl | 353 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 96 |
| Duloxetine Hcl | Duloxetine Hcl | 340 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 338 | 102 |
| Meloxicam | Meloxicam | 335 | 101 |
| Eliquis | Apixaban | 284 | 58 |
| Azithromycin | Azithromycin | 257 | 130 |
| Pravastatin Sodium | Pravastatin Sodium | 249 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 75 |
| Trazodone Hcl | Trazodone Hcl | 227 | 68 |
| Glimepiride | Glimepiride | 224 | 55 |
| Cephalexin | Cephalexin | 222 | 114 |
| Clopidogrel | Clopidogrel Bisulfate | 221 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 208 | 48 |
| Allopurinol | Allopurinol | 207 | 57 |
| Synthroid | Levothyroxine Sodium | 201 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 199 | 124 |
| Metformin Hcl | Metformin Hcl | 198 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 195 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 36 |
| Prednisone | Prednisone | 179 | 91 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 61 |
| Potassium Chloride | Potassium Chloride | 175 | 53 |
| Montelukast Sodium | Montelukast Sodium | 171 | 45 |
| Cefdinir | Cefdinir | 163 | 96 |
| Simvastatin | Simvastatin | 159 | 47 |
| Sertraline Hcl | Sertraline Hcl | 158 | 42 |
| Alendronate Sodium | Alendronate Sodium | 143 | 37 |
| Buspirone Hcl | Buspirone Hcl | 143 | 38 |
| Atenolol | Atenolol | 139 | 37 |
| Ondansetron Odt | Ondansetron | 138 | 51 |
| Finasteride | Finasteride | 137 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 34 |
| Warfarin Sodium | Warfarin Sodium | 131 | 29 |
| Amoxicillin | Amoxicillin | 129 | 64 |
| Donepezil Hcl | Donepezil Hcl | 124 | 35 |
| Fluconazole | Fluconazole | 124 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 31 |
| Glipizide Er | Glipizide | 119 | 34 |
| Pregabalin | Pregabalin | 118 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 115 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 30 |
| Enalapril Maleate | Enalapril Maleate | 110 | 30 |
| Spironolactone | Spironolactone | 110 | 31 |
| Mounjaro | Tirzepatide | 105 | 22 |
| Lorazepam | Lorazepam | 103 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 25 |
| Celecoxib | Celecoxib | 92 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 91 | 23 |
| Ozempic | Semaglutide | 90 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 48 |
| Estradiol | Estradiol | 86 | 23 |
| Carvedilol | Carvedilol | 84 | 27 |
| Clonazepam | Clonazepam | 83 | 17 |
| Eszopiclone | Eszopiclone | 83 | 14 |
| Lovastatin | Lovastatin | 83 | 22 |
| Ezetimibe | Ezetimibe | 80 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 13 |
| Ibuprofen | Ibuprofen | 75 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 66 | 19 |
| Chlorthalidone | Chlorthalidone | 64 | 19 |
| Jardiance | Empagliflozin | 64 | 17 |
| Mirtazapine | Mirtazapine | 64 | 18 |
| Glipizide | Glipizide | 63 | 19 |
| Valacyclovir | Valacyclovir Hcl | 61 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 20 |
| Xarelto | Rivaroxaban | 61 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 15 |
| Irbesartan | Irbesartan | 58 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 17 |
| Colestipol Hcl | Colestipol Hcl | 53 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 23 |
| Baclofen | Baclofen | 52 | 16 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 15 |
| Nitroglycerin | Nitroglycerin | 52 | 34 |
| Propranolol Hcl | Propranolol Hcl | 52 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Linzess | Linaclotide | 47 | 12 |
| Methocarbamol | Methocarbamol | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Nystatin | Nystatin | 46 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 44 | 13 |
| Diazepam | Diazepam | 43 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 43 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | suppressed |
| Mupirocin | Mupirocin | 42 | 32 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 13 |
| Lansoprazole | Lansoprazole | 38 | 14 |
| Promethazine Hcl | Promethazine Hcl | 38 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 16 |
| Novolog Flexpen | Insulin Aspart | 37 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 37 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Benzonatate | Benzonatate | 34 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Valsartan | Valsartan | 33 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 20 |
| Colchicine | Colchicine | 31 | 21 |
| Ibu | Ibuprofen | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 11 |
| Sulindac | Sulindac | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Novolog | Insulin Aspart | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $371.47 · 26 records | Novo Nordisk Inc | AREXVY, BodyGuardian, CAPVAXIVE, ELIQUIS, GARDASIL 9, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error